- Merck Stock Down 7% in a Month: Should Investors Hold or Exit?
May 11, 2026
Merck’s MRK stock has declined 7.3% in the past month despite announcing a solid first-quarter 2026 report on April 30. Merck beat estimates for both earnings and sales. Total revenues rose 5% to $16.3 billion, helped by strong growth from Keytruda and Winrevair. However, the company incurred a loss of $1.28 per share in the quarter due to a one-time charge of $3.62 per share related to the acquisition of Cidara, which closed in the first quarter. Even though the acquisition will benefit the company in the long run, a reported loss can limit investor optimism. The company also slightly raised its sales range, which may have been below investor expectations.
Also, in late April, the company faced a pipeline setback, which resulted in the stock’s recent sell-off. Merck and Eisai’s phase III LITESPARK-012 study evaluating two triplet combinations of blockbuster PD-L1 inhibitor, Keytruda plus Lenvima, failed to meet its main goals in previously untreated patients with advanced clear cell renal cell carcinoma, a common form of kidney cancer.
However, a single quarter’s results are not so important for long-term investors to make an investment decision. Let’s understand the company’s strengths and weaknesses to better analyze how to play Merck stock in the post-earnings scenario.
Keytruda: Merck’s Biggest Strength
Merck boasts more than six blockbuster drugs in its portfolio, with Keytruda being the key top-line driver. Keytruda, approved for several types of cancer, alone accounts for around 55% of the company’s pharmaceutical sales. Keytruda now holds 44 FDA-approved indications spanning 19 tumor types, along with two tumor-agnostic approvals.
The drug has played an instrumental role in driving Merck’s steady revenue growth over the past few years. Keytruda recorded sales of $8.0 billion in the first quarter of 2026, up 8% year over year.
Keytruda sales are gaining from continued strong momentum in metastatic indications and rapid uptake across earlier-stage launches. The company expects the growth to continue till it loses patent exclusivity in 2028.
Merck is working on different strategies to drive Keytruda's long-term growth. These include innovative immuno-oncology combinations, including Keytruda with LAG3 and CTLA-4 inhibitors. In partnership with Moderna MRNA, Merck is developing a personalized mRNA therapeutic cancer vaccine called intismeran autogene (V940/mRNA-4157) in combination with Keytruda in pivotal phase III studies for earlier-stage and adjuvant NSCLC and adjuvant melanoma.
Merck expects Keytruda to achieve peak sales of $35 billion by 2028. Merck’s other oncology drugs, Welireg, AstraZeneca (AZN)-partnered Lynparza and Eisai-partnered Lenvima, are also contributing to top-line growth.
Story Continues
Merck’s Animal Health business is also a key contributor to its top-line growth, with sales expected to more than double by mid-2030s.
MRK’s Pipeline Progress & Recent M&A Spree
Merck’s expanding drug pipeline and potential new blockbuster drugs beyond Keytruda look encouraging.
Its phase III pipeline has almost tripled since 2021, supported by in-house pipeline progress as well as the addition of candidates through M&A deals. Merck expects to launch 20 new drugs by 2030, with many already launched.
Some key new products with blockbuster potential are its 21-valent pneumococcal conjugate vaccine, Capvaxive, and pulmonary arterial hypertension drug, Winrevair. Both products have witnessed a strong launch and have the potential to generate significant revenues over the long term.
Merck’s RSV antibody, Enflonsia (clesrovimab), was approved in the United States in June 2025 and in the EU in April 2026. A once-daily, single-tablet two-drug regimen of doravirine and islatravir, Idvynso, was approved in the United States for virologically suppressed HIV-1 in April 2026.
Merck has other promising candidates in its late-stage pipeline, such as enlicitide decanoate/MK-0616, an oral PCSK9 inhibitor for hypercholesterolemia, tulisokibart, a TL1A inhibitor for ulcerative colitis and Daiichi-Sankyo-partnered antibody-drug conjugates.
Merck has been on an acquisition spree in the past year, as it faces the looming patent expiration of Keytruda in 2028. The acquisition of Verona in 2025 added Ohtuvayre, a novel, first-in-class maintenance treatment for chronic obstructive pulmonary disease, with multibillion-dollar commercial potential. Ohtuvayre's commercial launch is off to a solid start.
In January 2026, Merck acquired Cidara Therapeutics, which added its lead pipeline candidate, MK-1406 (formerly CD388), a first-in-class long-acting, strain-agnostic antiviral agent, currently being evaluated in late-stage studies for the prevention of seasonal influenza in individuals at higher risk of complications.
In April 2026, it acquired California-based cancer biotech, Terns Pharmaceuticals, which added Terns’ lead chronic myeloid leukemia candidate, TERN-701, a novel oral allosteric inhibitor of the BCR::ABL oncogene, to Merck’s hematology/cancer pipeline. Merk believes TERN-701 has multibillion-dollar commercial potential.
Declining Sales of MRK’s Gardasil & Other Vaccines
Sales of Merck’s second-largest product, its HPV vaccine, Gardasil, plunged 22% to $1.07 billion in the first quarter due to continued weak sales performance in China. Sales of Gardasil are declining in China due to weak demand trends amid an economic slowdown. The company is also seeing lower demand for the vaccine in Japan. Gardasil sales are not expected to improve in 2026.
Sales of some other Merck vaccines, like Proquad, M-M-R II, Varivax, Rotateq and Vaxneuvance, also declined in the first quarter.
MRK’s Keytruda Faces Patent Expiration in 2028
Merck is heavily reliant on Keytruda. Though Keytruda may be Merck’s biggest strength and a solid reason to own the stock, the company is excessively dependent on the drug. Keytruda’s core U.S. patent is expected to expire around 2028, with additional patents expiring slightly after that. Keytruda is expected to face significant biosimilar competition around 2028-2029. Once biosimilars enter, Keytruda’s sales are likely to decline sharply.
Also, competitive pressure might increase for Keytruda in the near future from dual PD-1/VEGF inhibitors that inhibit both the PD-1 pathway and the VEGF pathway at once. They are designed to overcome the limitations of single-target therapies like Keytruda.
MRK’s Generic Headwinds in 2026
MRK is seeing declining demand for its diabetes products (Januvia/Janumet) and the generic erosion of some drugs like Isentress/Isentress HD and Bridion in the European Union and Dificid in the United States. Bridion is expected to lose patent exclusivity in the United States in July 2026, and sales are expected to significantly decline thereafter. Sales of Januvia/Janumet are expected to decline steeply from 2026 onward due to government price setting, an anticipated patent expiry in 2026 and ongoing competitive pressure.
In 2026, Merck expects generic competition for Januvia/Janumet, Bridion and Dificid to hurt revenues by approximately $2.5 billion.
MRK Share Price, Valuation & Estimates
Merck’s shares have risen 38.4% in the past year compared with an increase of 17.3% for the industry. The stock has also outperformed the sector as well as the S&P 500 index.
Merck Stock Outperforms Industry, Sector & S&P 500Zacks Investment Research
Image Source: Zacks Investment Research
From a valuation standpoint, Merck looks slightly expensive. Going by the price/earnings ratio, the company’s shares currently trade at 16.79 forward earnings, slightly higher than 16.40 for the industry. The stock is also trading above its 5-year mean of 12.70. However, the stock is cheaper than other drugmakers like Eli Lilly LLY and J&J JNJ.
MRK Stock ValuationZacks Investment Research
Image Source: Zacks Investment Research
Estimates for MRK’s 2026 earnings have risen from $4.87 to $4.88 per share over the past 30 days, while those for 2027 have declined from $9.85 per share to $9.77 per share.
MRK Estimate MovementZacks Investment Research
Image Source: Zacks Investment Research
Stay Invested in MRK Stock
Merck has one of the world’s best-selling drugs in its portfolio, generating billions of dollars in revenues. Though Keytruda will lose patent exclusivity in 2028, its sales are expected to remain strong until then. Merck’s new products, Winrevair, Welireg and Capvaxive, key pipeline progress and expansion of its respiratory and infectious disease and oncology portfolios through the acquisitions of Verona Pharma, Cidara Therapeutics and Terns Pharmaceuticals have improved its long-term growth prospects.
Merck expects over $70 billion of potential non-risk-adjusted commercial opportunity for the current pipeline by the mid-2030s. This estimate is more than double the peak consensus sales estimate for Keytruda of $35 billion in 2028. Merck said that the estimate of $70 billion was $20 billion higher than what they expected just one year ago.
The new products and strong progress in its pipeline have increased confidence that Merck may be able to maintain growth even after Keytruda loses exclusivity.
However, Merck faces several near-term challenges, including persistent challenges for Gardasil in China, potential competition for Keytruda, and rising competitive and generic pressure on some of its drugs. Also, estimates have declined recently due to costs related to its various M&A deals.
Long-term investors may continue retaining this Zacks Rank #3 (Hold) stock and see how the company manages its future product and pipeline growth and replaces Keytruda revenues. However, short-term investors may reduce their position in the stock as there seems to be limited prospects for growth in the near term. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
Merck & Co., Inc. (MRK) : Free Stock Analysis Report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
Moderna, Inc. (MRNA) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Talvey (Johnson & Johnson: talquetamab-tgvs) Market Research Report 2026: Epidemiology, Pipeline Analysis, Insights & Forecasts, 2020-2025, 2025-2030F, 2035F
May 11, 2026
Company Logo
Key market opportunities in the Talvey market include rising prevalence of autoimmune diseases, increasing healthcare expenditures, and expanding biosimilar development. The market is driven by personalized immunotherapy, targeted therapies, digital monitoring tools, and regional production amid tariff pressures.
Dublin, May 11, 2026 (GLOBE NEWSWIRE) -- The "Talvey Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.
The Talvey Market Global Report 2026 provides essential insights for strategists, marketers, and senior management to assess a rapidly expanding market. This comprehensive report guides readers through the emerging trends set to shape the industry over the next decade and beyond. The Talvey market encompasses sales of biosimilars, monoclonal antibodies, corticosteroids, and immunosuppressants. It reflects 'factory gate' values, indicating revenues generated from primary sales inside the market's geographical scope.
The Talvey market, particularly known for its role in treating autoimmune disorders, has witnessed substantial growth. This uptrend is attributed to the increasing prevalence of autoimmune disorders, more biologic drug approvals, heightened awareness of disease-modifying therapies, improved diagnostic capabilities, and enhanced access to specialty care. As we look into the future, the market is poised to benefit from the adoption of personalized immunotherapies, significant investments in biosimilar development, expansion of digital patient monitoring, and a focus on cost-effective biologic alternatives, facilitating long-term treatment adherence.
Emerging trends include a growing use of targeted autoimmune therapies, biosimilars in chronic disease management, and precision-based treatment protocols, all aimed at long-term disease control and improved patient monitoring.
The Talvey market's prospects are brightened by the rising prevalence of autoimmune diseases, often driven by genetic factors, environmental triggers, lifestyle alterations, and increased awareness. Talvey (natalizumab-sztn), a therapeutic agent targeting integrins, plays a significant role in reducing inflammation by preventing immune cell infiltration into the central nervous system, aiding conditions such as multiple sclerosis and Crohn's disease. In 2025, the Mayo Clinic estimated that 15 million individuals suffer from autoimmune diseases, highlighting a strong demand for treatments like Talvey.
Market growth is also driven by rising healthcare expenditures. Factors such as an aging population, the prevalence of chronic diseases, and rising healthcare demands contribute to this increase. Enhanced healthcare spending ensures wider access to Talvey, making it more affordable for patients. For instance, the OECD reported an average healthcare expenditure of 9.3% of GDP among member countries in 2024, emphasizing the significance of healthcare investments in supporting drug availability.
Story Continues
Key players like Janssen Pharmaceutical Companies of Johnson & Johnson focus heavily on drug approvals to bolster their market position. Notably, in August 2023, Janssen announced FDA approval for TALVEY (talquetamab-tgvs), a novel bispecific antibody for treating relapsed or refractory multiple myeloma, showcasing its targeted approach and flexible dosing.
Regionally, North America stood as the largest market in 2025, while Europe is anticipated to exhibit rapid growth. Countries of interest include the USA, Canada, the UK, Germany, China, and India. However, tariffs impact the market by inflating costs of imported biologic inputs, influencing pricing and supply chain dynamics primarily in North America and Europe.
Report Scope:
Markets Covered: Formulations: 3mg/1.5ml, 40mg/ml Clinical Indications: Relapsed/Refractory Multiple Myeloma, Monotherapy Distribution Channels: Hospital, Specialty, Online Pharmacies End Users: Adult, Geriatric Companies Mentioned: Johnson & Johnson Countries Covered: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa Time Series: Five years of historical data and a ten-year forecast
For more information about this report visit https://www.researchandmarkets.com/r/x7mv5g
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
View Comments
- FarmaMondo Group appoints Independent Board Director Natalie Douglas, global pharmaceutical managed access and commercialization pioneer
May 11, 2026
PRINCETON, N.J. and CHIASSO, Switzerland, May 11, 2026 /PRNewswire/ -- FarmaMondo Group, an international commercial pharmaceutical organization that partners with pharma and biotech to deliver innovative and specialty medicines to the 50+ emerging markets, today announces the appointment of Natalie Douglas as Independent Board Director. Douglas is best known for pioneering the managed access to commercialization drug program, now the accepted model for how the pharmaceutical industry delivers access to many international markets.
After a career in leadership at J&J, Douglas built IDIS, an international specialty pharmaceutical organization headquartered in Princeton, NJ. Douglas transformed IDIS into the leading global provider of managed access programs, delivering over 200 global access programs on behalf of 40 pharmaceutical and biotech companies for serious and rare conditions. The company was subsequently acquired by Clinigen Group, validating the transformative commercial value of Douglas's model. Under her visionary leadership, IDIS proved that expanded access could be delivered systematically, ethically, and at scale so that patients all over the world had access to life-saving medicines.
"Natalie Douglas is one of the most significant figures in global patient access, credited with developing the industry standard for managed access programs and connecting pharma companies to healthcare facilities in hard-to-reach places around the world," said Yaron Spigel, FarmaMondo CEO. "Natalie's appointment to our board is pivotal as FarmaMondo expands its partnership base with U.S.-based pharmaceutical and biotech companies seeking to comprehensively serve patients around the globe."
FarmaMondo is at an inflection point in its growth trajectory as it rapidly expands its footprint in the U.S. market. It has 14 regional affiliates and an oncology, specialty and rare disease portfolio that represents more than 50 therapies across 50 countries. Critically, FarmaMondo delivers commercial patient access with a novel model unmatched in the industry. Douglas' historic leadership positions her as an ideal board member for the company's expanded presence in the U.S. market.
"It's a privilege to lend my global access expertise to FarmaMondo and help them expand their U.S. market presence," said Natalie Douglas, FarmaMondo Board Director. "I am impressed with what Yaron and his team have built to drive the future model of international market access; FarmaMondo's work with their pharma partners aligns with my passion to help patients in dire need of life-changing medicines that live outside the traditional geography of major markets."
Story Continues
About FarmaMondo Group
FarmaMondo Group is a pharmaceutical organization that delivers pharmaceutical companies with a turnkey, integrated market presence across 50+ emerging markets, from early access through commercialization, bringing vital medicines to patients in need. With 14 regional affiliates, a proven track record across 50+ assets and a portfolio spanning oncology, hematology, endocrinology, neurology and metabolic diseases, FarmaMondo is committed to ensuring that life-changing therapies reach patients in every corner of the world.
Media Contact Ivy Cohen
Ivy Cohen Corporate Communications
+1 (212) 399-0026
ivy@ivycohen.comCision
View original content:https://www.prnewswire.com/news-releases/farmamondo-group-appoints-independent-board-director-natalie-douglas-global-pharmaceutical-managed-access-and-commercialization-pioneer-302767569.html
View Comments
- Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP
May 11, 2026
Oral presentations feature CAPLYTA® long-term data assessing relapse risk reduction in schizophrenia and new seltorexant analyses in major depressive disorder (MDD) with insomnia symptoms
18 abstracts highlight J&J's leadership and deep portfolio in neuropsychiatry at the American Psychiatric Association (APA) and American Society of Clinical Psychopharmacology (ASCP) Annual Meetings
TITUSVILLE, N.J., May 11, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that 18 abstracts featuring new and encore data from the Company's robust neuropsychiatry portfolio and pipeline will be presented at two upcoming scientific meetings: the American Psychiatric Association (APA) Annual Meeting (May 16-20, San Francisco) and the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (May 26-29, Miami). The presentations will highlight the Company's latest research across key neuropsychiatric disorders, including major depressive disorder (MDD), treatment‑resistant depression (TRD) and schizophrenia.Johnson & Johnson (PRNewsfoto/Johnson & Johnson)
"At Johnson & Johnson, we are focused on addressing the residual symptoms that standard treatments often miss for the millions of patients living with some of today's most prevalent and debilitating neuropsychiatric conditions," said Jane Tiller, FRC Psych (MD), MBA, MPhil, Vice President Global Head of Development, Neuroscience, Innovative Medicine, Johnson & Johnson. "The depth of data being presented across indications at these two meetings underscores our commitment to advancing safe, effective treatment options that may move more patients closer to sustained symptom control, including remission."
Meeting highlights include:
American Psychiatric Association (APA) Annual Meeting
CAPLYTA® (lumateperone): Oral presentation featuring long-term data from CAPLYTA® Phase 3 study evaluating safety and efficacy for the prevention of relapse in schizophrenia.1 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Seltorexant: Oral presentation will showcase key data from Phase 3 studies evaluating efficacy as adjunctive therapy in adults with MDD and insomnia symptoms, and poster presentations exploring the impact of seltorexant on cognitive performance and the post-hoc analysis of metabolic outcomes in adults with MDD and insomnia symptoms.2,3,4 CAPLYTA® (lumateperone): Multiple poster presentations featuring new analyses from pivotal Phase 3 studies evaluating MDD remission outcomes and efficacy across patient subgroups when used as adjunctive treatment compared with placebo.5-11 SPRAVATO® (esketamine) CIII Nasal Spray: Poster presentation featuring post‑hoc analyses from the Phase 3 SUSTAIN‑1 long‑term study examining predictors of relapse among patients with TRD who achieved response or remission.12 Long-Acting Injectables (LAIs): How to Present Long‑Acting Injectables (LAIs) Effectively (HoPE LAI) Consensus panel focused on recommendations from nurse practitioners (NPs) and physician assistants (PAs) for engaging patients and caregivers in discussions about LAI treatment options for schizophrenia.13
Story Continues
The full list of Johnson & Johnson data presentations at APA and ASCP is available on JNJ.com.
ABOUT MAJOR DEPRESSIVE DISORDER (MDD)
MDD is one of the most common psychiatric disorders and a leading cause of disability worldwide, impacting an estimated 332 million people – or about 4 percent of the population.14,15 In 2023, approximately 22 million adults in the U.S. had at least one major depressive episode.16 While depression is typically treated with a "one-size-fits-all" approach, no two cases are the same. MDD is a complex, heterogeneous disorder involving multiple regions of the brain and presenting with as many as 256 unique symptom combinations.17,18 As a result, responses to treatment vary widely. Only 1 in 3 patients reach remission with their first antidepressant – and rates continue to decline further with each subsequent treatment, leaving many to spend years cycling through multiple treatments trying to find complete, sustained symptom relief.19 Moreover, MDD is a risk factor for the development and worsening of a range of comorbidities, illustrating the importance of integrating mental and general health care.20
MDD often includes sleep disturbances such as insomnia or hypersomnia, with approximately 60 percent of MDD patients experiencing clinically relevant insomnia symptoms despite being on an SSRI/SNRI.21 Disturbed sleep and insomnia symptoms have a significant impact on a patient's quality of life and exacerbate the risk of depressive relapse and suicide.22,23
Approximately one-third of adults with MDD will not respond to oral antidepressants alone and are considered to have treatment-resistant depression (TRD), which is often defined as inadequate response to two or more oral antidepressants that were administered at an adequate dose for an adequate duration.24,25 TRD has a significant negative impact on the lives of those affected and has one of the highest economic burdens of all psychiatric disorders.25 Patients often cycle through multiple oral medications, waiting 4-6 weeks for potential relief.26 Based on the STAR*D study, after their third line of treatment, approximately 86 percent of patients do not achieve remission.26
About Schizophrenia Schizophrenia is a complex, chronic brain disorder that affects how people think, feel, speak, and act. It affects up to an estimated 2.8 million adults in the United States yet remains widely misunderstood and insufficiently treated.27 Symptoms vary by person, but confusion and distortions in perceptions, emotions, and behavior are common.28 Evidence shows that the first three to five years after diagnosis — "the critical period" — from symptom onset are key for a patient's treatment, as this is when the condition progresses most rapidly.29,30 A comprehensive treatment plan, which may include medication, therapy, and psychosocial services, is critical in delaying the time to relapse for adults with schizophrenia.31
About CAPLYTA® (lumateperone)
CAPLYTA® 42 mg is an oral, once daily atypical antipsychotic approved in adults as an adjunctive therapy with antidepressants for major depressive disorder (MDD), schizophrenia, and depressive episodes associated with bipolar I or II disorder (bipolar depression), as monotherapy, and as adjunctive therapy with lithium or valproate.
While the mechanism of action of CAPLYTA® is unknown, the efficacy of CAPLYTA® could be mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and partial agonist activity at central dopamine D2 receptors.
About Seltorexant Seltorexant, an investigational first-in-class therapy, is a selective antagonist of the human orexin-2 receptor currently being developed as an adjunctive treatment for adults with MDD with insomnia symptoms. Seltorexant selectively antagonizes the orexin-2 receptors, potentially improving mood symptoms associated with depression and restoring sleep without next-day sedation in patients with depression.32 When orexin-2 receptors are stimulated for too long or at inappropriate times, their activation can cause hyperarousal manifestations, including insomnia and excessive cortisol release, which may contribute to depression and insomnia.33,34 Seltorexant is the only investigational therapy under study for the treatment of MDD that is believed to work by normalizing the overactivation of the orexin-2 receptors, thereby targeting the underlying biology that contributes to depression and insomnia symptoms.
ABOUT SPRAVATO® (esketamine) CIII nasal spray SPRAVATO® is approved by the U.S. Food and Drug Administration alone or in conjunction with an oral antidepressant for adults with MDD when they have inadequate response to at least two oral antidepressants (TRD) and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant. It is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor and is believed to work differently than traditional antidepressants by acting on a pathway in the brain that affects glutamate. The mechanism by which esketamine exerts its antidepressant effect is unknown. To date, SPRAVATO® has been approved in 77 markets and administered to more than 235,000 patients worldwide.
ABOUT J&J'S SCHIZOPHRENIA LONG-ACTINGINJECTABLE (LAI) PORTFOLIO
Johnson & Johnson's portfolio of long-acting injectable (LAI) offerings for schizophrenia offers the a varied range of dosing options and the longest-lasting schizophrenia treatments with each dose available, including INVEGA SUSTENNA® (1-month paliperidone palmitate), INVEGA TRINZA® (3-month paliperidone palmitate), and INVEGA HAFYERA® (6-month paliperidone palmitate), all of which are administered in a clinical setting by a medical professional.28,29
CAPLYTA® IMPORTANT SAFETY INFORMATION
INDICATIONS
CAPLYTA® (lumateperone) is a prescription medicine used in adults along with an antidepressant to treat major depressive disorder (MDD); to treat depressive episodes associated with bipolar I or bipolar II disorder (bipolar depression) alone or with lithium or valproate; or to treat schizophrenia. It is not known if CAPLYTA is safe and effective in children.
IMPORTANT SAFETY INFORMATION
Medicines like CAPLYTA can raise the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). CAPLYTA is not approved for treating people with dementia-related psychosis.
CAPLYTA and antidepressant medicines increase the risk of suicidal thoughts and actions in people 24 years of age and younger, especially within the first few months of treatment or when the dose is changed. Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Patients and their families or caregivers should watch for new or worsening depression symptoms, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when CAPLYTA or an antidepressant medicine is started or when the dose is changed. Report any changes in these symptoms to your healthcare provider immediately.
Do not take CAPLYTA if you are allergic to any of its ingredients. Get emergency medical help if you are having an allergic reaction (e.g., rash, itching, hives, swelling of the tongue, lip, face, or throat).
CAPLYTA may cause serious side effects, including:
Stroke (cerebrovascular problems) in elderly people with dementia-related psychosis that can lead to death. Neuroleptic malignant syndrome (NMS): high fever, confusion, changes in your breathing, heart rate, and blood pressure, stiff muscles, and increased sweating; these may be symptoms of a rare but potentially fatal condition. Contact your healthcare provider or go to the emergency room if you experience signs and symptoms of NMS. Uncontrolled body movements (tardive dyskinesia, TD) in your face, tongue, or other body parts. TD may not go away, even if you stop taking CAPLYTA. It may also occur after you stop taking CAPLYTA. Problems with your metabolism including high blood sugar, diabetes, increased fat (cholesterol and triglyceride) levels in your blood and weight gain. Your healthcare provider should check your blood sugar, fat levels, and weight before you start and during your treatment with CAPLYTA. Extremely high blood sugar levels can lead to coma or death. Call your healthcare provider if you have any of the following symptoms of high blood sugar: feeling very thirsty, hungry, sick to your stomach, needing to urinate more than usual, weak/tired, or confused, or your breath smells fruity. Low white blood cell count. Your healthcare provider may do blood tests during the first few months of treatment with CAPLYTA. Decreased blood pressure (orthostatic hypotension). You may feel lightheaded, dizzy, or faint when you rise too quickly from a sitting or lying position. Falls. CAPLYTA may make you sleepy or dizzy, may cause a decrease in your blood pressure when changing position (orthostatic hypotension), and can slow your thinking and motor skills which may lead to falls that can cause broken bones or other injuries. Seizures (convulsions). Sleepiness, drowsiness, feeling tired, difficulty thinking and doing normal activities. Until you know how CAPLYTA affects you, do not drive, operate heavy machinery, or do other dangerous activities. Problems controlling your body temperature so that you feel too warm. Avoid getting overheated or dehydrated while taking CAPLYTA. Difficulty swallowing that can cause food or liquid to get into the lungs.
The most common side effects of CAPLYTA include sleepiness, dizziness, nausea, dry mouth, feeling tired, and diarrhea.
These are not all the possible side effects of CAPLYTA. Tell your healthcare provider if you have or have had heart problems or a stroke, high or low blood pressure, diabetes, or high blood sugar, problems with cholesterol, have or have had a low white blood cell count, seizures (convulsions), or kidney or liver problems.
CAPLYTA may cause fertility problems in females and males. You should notify your healthcare provider if you become pregnant or intend to become pregnant while taking CAPLYTA. There is a pregnancy registry for females who are exposed to CAPLYTA during pregnancy. CAPLYTA may cause abnormal involuntary movements and/or withdrawal symptoms in newborn babies exposed to CAPLYTA during the third trimester. Talk to your healthcare provider if you breastfeed or are planning to breastfeed as CAPLYTA passes into breast milk.
Tell your healthcare provider about all the medicines you're taking. CAPLYTA may affect the way other medicines work, and other medicines may affect how CAPLYTA works, causing possible serious side effects. Do not start or stop any medicines while taking CAPLYTA without talking to your healthcare provider. You are encouraged to report negative side effects of prescription drugs. Contact Intra-Cellular Therapies, Inc. at 1-888-611-4824 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
CAPLYTA is available in 42 mg, 21 mg, and 10.5 mg capsules.
US-CAP-2500827
Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for CAPLYTA.
INVEGASUSTENNA®, INVEGA TRINZA®, INVEGA HAFYERA® IMPORTANT SAFETY INFORMATION
INDICATIONS
INVEGA HAFYERA® (6-month paliperidone palmitate) is a prescription medicine given by injection every 6 months by a healthcare professional and used to treat schizophrenia. INVEGA HAFYERA® is used in adults who have been treated with either:
INVEGA SUSTENNA® (paliperidone palmitate) a 1-time-each-month paliperidone palmitate extended-release injectable suspension for at least 4 months INVEGA TRINZA® (paliperidone palmitate) a 1-time-every-3-months paliperidone palmitate extended-release injectable suspension for at least 3 months
INVEGA TRINZA® is a prescription medicine given by injection every 3 months by a healthcare professional and used to treat schizophrenia. INVEGA TRINZA® is used in people who have been adequately treated with INVEGA SUSTENNA® for at least 4 months.
INVEGA SUSTENNA® is a prescription medicine given by injection by a healthcare professional.
INVEGA SUSTENNA® is used to treat schizophrenia in adults.
INVEGA SUSTENNA®, INVEGA TRINZA®, INVEGA HAFYERA® IMPORTANT SAFETY INFORMATION
What is the most important information I should know about INVEGA HAFYERA®,
INVEGA TRINZA® and INVEGA SUSTENNA®?
INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® may cause serious side effects, including:
Increased risk of death in elderly people with dementia-related psychosis.
INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® increase the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® are not for the treatment of people with dementia-related psychosis.
Do not receive INVEGA HAFYERA®,INVEGA TRINZA® or INVEGA SUSTENNA® if you are allergic to paliperidone, paliperidone palmitate, risperidone, or any of the ingredients in INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®. See the end of the Patient Information leaflet in the full Prescribing Information for a complete list of INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® ingredients.
Before you receive INVEGA HAFYERA®,INVEGA TRINZA® or INVEGA SUSTENNA®, tell your healthcare professional about all your medical conditions, including if you:
have had Neuroleptic Malignant Syndrome (NMS) have or have had heart problems, including a heart attack, heart failure, abnormal heart rhythm, or long QT syndrome have or have had low levels of potassium or magnesium in your blood have or have had uncontrolled movements of your tongue, face, mouth, or jaw (tardive dyskinesia) have or have had kidney or liver problems have diabetes or have a family history of diabetes have Parkinson's disease or a type of dementia called Lewy Body Dementia have had a low white blood cell count have had problems with dizziness or fainting or are being treated for high blood pressure have or have had seizures or epilepsy have any other medical conditions are pregnant or plan to become pregnant. It is not known if INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® will harm your unborn baby
If you become pregnant while taking INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®, talk to your healthcare professional about registering with the National Pregnancy Registry for Atypical Antipsychotics. You can register by calling 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry. Infants born to women who are treated with INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® may experience symptoms such as tremors, irritability, excessive sleepiness, eye twitching, muscle spasms, decreased appetite, difficulty breathing, or abnormal movement of arms and legs. Let your healthcare professional know if these symptoms occur. are breastfeeding or plan to breastfeed. INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®
can pass into your breast milk. Talk to your healthcare professional about the best way to feed your baby if you receive INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®.
Tell your healthcare professional about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® may affect the way other medicines work, and other medicines may affect how INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® works.
Your healthcare provider can tell you if it is safe to receive INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® with your other medicines. Do not start or stop any medicines during treatment with INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® without talking to your healthcare provider first. Know the medicines you take. Keep a list of them to show to your healthcare professional or pharmacist when you get a new medicine.
Patients (particularly the elderly) taking antipsychotics with certain health conditions or those on long-term therapy should be evaluated by their healthcare professional for the potential risk of falls.
How will I receive INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®?
Follow your treatment schedule exactly as your healthcare provider tells you to. Your healthcare provider will tell you how much you will receive and when you will receive it.
What should I avoid while receiving INVEGA HAFYERA®, INVEGA TRINZA® or
INVEGA SUSTENNA®?
INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® may affect your ability to make decisions, think clearly, or react quickly. Do not drive, operate heavy machinery, or do other dangerous activities until you know how INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® affects you. Avoid getting overheated or dehydrated.
INVEGA HAFYERA®,INVEGA TRINZA® and INVEGA SUSTENNA® may cause serious side effects, including:
See "What is the most important information I should know aboutINVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA®?" stroke in elderly people (cerebrovascular problems) that can lead to death Neuroleptic Malignant Syndrome (NMS). NMS is a rare but very serious problem that can happen in people who receive INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®. NMS can cause death and must be treated in a hospital. Call your healthcare professional right away if you become severely ill and have any of these symptoms: high fever; severe muscle stiffness; confusion; loss of consciousness; changes in your breathing, heartbeat, and blood pressure. problems with your heartbeat. These heart problems can cause death. Call your healthcare professional right away if you have any of these symptoms: passing out or feeling like you will pass out, dizziness, or feeling as if your heart is pounding or missing beats. uncontrolled movements of your tongue, face, mouth, or jaw (tardive dyskinesia) metabolic changes. Metabolic changes may include high blood sugar (hyperglycemia), diabetes mellitus and changes in the fat levels in your blood (dyslipidemia), and weight gain. low blood pressure and fainting changes in your blood cell counts high level of prolactin in your blood (hyperprolactinemia). INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® may cause a rise in the blood levels of a hormone called prolactin (hyperprolactinemia) that may cause side effects including missed menstrual periods, leakage of milk from the breasts, development of breasts in men, or problems with erection. problems thinking clearly and moving your body seizures difficulty swallowing that can cause food or liquid to get into your lungs prolonged or painful erection lasting more than 4 hours. Call your healthcare professional or go to your nearest emergency room right away if you have an erection that lasts more than 4 hours. problems with control of your body temperature, especially when you exercise a lot or spend time doing things that make you warm. It is important for you to drink water to avoid dehydration.
The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory tract infections, feeling restlessness or difficulty sitting still, slow movements, tremors, stiffness and shuffling walk.
The most common side effects of INVEGA TRINZA® include: injection site reactions, weight gain, headache, upper respiratory tract infections, feeling restlessness or difficulty sitting still, slow movements, tremors, stiffness and shuffling walk.
The most common side effects of INVEGA SUSTENNA® include: injection site reactions; sleepiness or drowsiness; dizziness; feeling of inner restlessness or needing to be constantly moving; abnormal muscle movements, including tremor (shaking), shuffling, uncontrolled involuntary movements, and abnormal movements of your eyes.
Tell your healthcare professional if you have any side effect that bothers you or does not go away. These are not all the possible side effects of INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®. For more information, ask your healthcare professional or pharmacist.
Call your healthcare professional for medical advice about side effects.You may report side effects of prescription drugs to the FDA at 1-800-FDA-1088.
General information about the safe and effective use of INVEGA HAFYERA®,INVEGA TRINZA® or INVEGA SUSTENNA®
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.
Do not use INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® for a condition for which it was not prescribed. You can ask your pharmacist or healthcare professional for information about INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® that is written for healthcare professionals.
For more information, go to www.invegahafyera.com, www.invegatrinza.com or www.invegasustenna.com or call 1-800-526-7736.
Please click to read the full Prescribing Information, including Boxed WARNING, for INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® and discuss any questions you have with your healthcare professional.
cp-256259v4
SPRAVATO® IMPORTANT SAFETY INFORMATION
What is SPRAVATO® (esketamine) CIII nasal spray?
SPRAVATO® is a prescription medicine used:
with or without an antidepressant taken by mouth, to treat adults with treatment-resistant depression (TRD) with an antidepressant taken by mouth, to treat depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions
SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine.
It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.
It is not known if SPRAVATO® is safe and effective in children.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about SPRAVATO®?
SPRAVATO® can cause serious side effects, including:
Sedation, dissociation, and respiratory depression. SPRAVATO® may cause sleepiness (sedation), fainting, dizziness, spinning sensation, anxiety, or feeling disconnected from yourself, your thoughts, feelings, space and time (dissociation), breathing problems (respiratory depression and respiratory arrest)
Tell your healthcare provider right away if you feel like you cannot stay awake or if you feel like you are going to pass out. Your healthcare provider must monitor you for serious side effects for at least 2 hours after taking SPRAVATO®. Your healthcare provider will decide when you are ready to leave the healthcare setting.
Abuse and misuse. There is a risk for abuse and misuse with SPRAVATO®, which may lead to physical and psychological dependence. Your healthcare provider should check you for signs of abuse, misuse, and dependence before and during treatment.
Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs. Your healthcare provider can tell you more about the differences between physical and psychological dependence and drug addiction.
SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS). Because of the risks for sedation, dissociation, respiratory depression and abuse and misuse, SPRAVATO® is only available through a restricted program called the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program. SPRAVATO® can only be administered at healthcare settings certified in the SPRAVATO® REMS Program. Patients treated in outpatient healthcare settings (such as medical offices and clinics) must be enrolled in the program.
Increased risk of suicidal thoughts and actions. Antidepressant medicines may increase suicidal thoughts and actions in some people 24 years of age and younger, especially within the first few months of treatment or when the dose is changed. SPRAVATO® is not for use in children.
Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a higher risk of having suicidal thoughts or actions. These include people who have (or have a family history of) depression or a history of suicidal thoughts or actions.
How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?
Pay close attention to any changes, especially sudden changes, in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions. Tell your healthcare provider right away if you have any new or sudden changes in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions. Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms.
Tell your healthcare provider or get emergency help right away if you or your family member have any of the following symptoms, especially if they are new, worse, or worry you:
thoughts about suicide or dying
new or worse depression
feeling very agitated or restless
trouble sleeping (insomnia)
acting aggressive, being angry or violent an extreme increase in activity and talking (mania) suicide attempts
new or worse anxiety
panic attacks
new or worse irritability
acting on dangerous impulses other unusual changes in behavior or mood
Do not take SPRAVATO® if you:
have blood vessel (aneurysmal vascular) disease (including in the brain, chest, abdominal aorta, arms and legs) have an abnormal connection between your veins and arteries (arteriovenous malformation) have a history of bleeding in the brain are allergic to esketamine, ketamine, or any of the other ingredients in SPRAVATO®.
If you are not sure if you have any of the above conditions, talk to your healthcare provider before taking SPRAVATO®.
Before you take SPRAVATO®, tell your healthcare provider about all of your medical conditions, including if you:
have heart or brain problems, including:
high blood pressure (hypertension) slow or fast heartbeats that cause shortness of breath, chest pain, lightheadedness, or fainting history of heart attack history of stroke heart valve disease or heart failure history of brain injury or any condition where there is increased pressure in the brain have liver problems have ever had a condition called "psychosis" (see, feel, or hear things that are not there, or believe in things that are not true). are pregnant or plan to become pregnant. SPRAVATO® may harm your unborn baby. You should not take SPRAVATO® if you are pregnant.
Tell your healthcare provider right away if you become pregnant during treatment with SPRAVATO®. If you are able to become pregnant, talk to your healthcare provider about methods to prevent pregnancy during treatment with SPRAVATO®. There is a pregnancy registry for women who are exposed to SPRAVATO® during pregnancy. The purpose of the registry is to collect information about the health of women exposed to SPRAVATO® and their baby. If you become pregnant during treatment with SPRAVATO®, talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or online at https://womensmentalhealth.org/clinical-and-research- programs/pregnancyregistry/antidepressants/. are breastfeeding or plan to breastfeed. SPRAVATO® passes into your breast milk. You should not breastfeed during treatment with SPRAVATO®.
Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Taking SPRAVATO® with certain medicine may cause side effects.
Especially tell your healthcare provider if you take central nervous system (CNS) depressants, psychostimulants, or monoamine oxidase inhibitors (MAOIs) medicines. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.
How will I take SPRAVATO®?
You will take SPRAVATO® nasal spray yourself, under the supervision of a healthcare provider in a healthcare setting. Your healthcare provider will show you how to use the SPRAVATO® nasal spray device. Your healthcare provider will tell you how much SPRAVATO® you will take and when you will take it. Follow your SPRAVATO® treatment schedule exactly as your healthcare provider tells you to. During and after each use of the SPRAVATO® nasal spray device, you will be checked by a healthcare provider who will decide when you are ready to leave the healthcare setting. You will need to plan for a caregiver or family member to drive you home after taking SPRAVATO®. If you miss a SPRAVATO® treatment, your healthcare provider may change your dose and treatment schedule. Some people taking SPRAVATO® get nausea and vomiting. You should not eat for at least 2 hours before taking SPRAVATO® and not drink liquids at least 30 minutes before taking SPRAVATO®. If you take a nasal corticosteroid or nasal decongestant medicine take these medicines at least 1 hour before taking SPRAVATO®.
What should I avoid while taking SPRAVATO®?
Do not drive, operate machinery, or do anything where you need to be completely alert after taking SPRAVATO®. Do not take part in these activities until the next day following a restful sleep. See "What is the most important information I should know about SPRAVATO®?"
What are the possible side effects of SPRAVATO®?
SPRAVATO® may cause serious side effects including:
See "What is the most important information I should know about SPRAVATO®?"
Increased blood pressure. SPRAVATO® can cause a temporary increase in your blood pressure that may last for about 4 hours after taking a dose. Your healthcare provider will check your blood pressure before taking SPRAVATO® and for at least 2 hours after you take SPRAVATO®. Tell your healthcare provider right away if you get chest pain, shortness of breath, sudden severe headache, change in vision, or seizures after taking SPRAVATO®.
Problems with thinking clearly. Tell your healthcare provider if you have problems thinking or remembering.
Bladder problems. Tell your healthcare provider if you develop trouble urinating, such as a frequent or urgent need to urinate, pain when urinating, or urinating frequently at night.
The most common side effects of SPRAVATO® include:
feeling disconnected from yourself, your thoughts,
feelings and things around you
dizziness
nausea
feeling sleepy
spinning sensation decreased feeling of sensitivity (numbness) feeling anxious
lack of energy
increased blood pressure
vomiting
feeling drunk
headache feeling very happy or excited
If these common side effects occur, they usually happen right after taking SPRAVATO® and go away the same day.
These are not all the possible side effects of SPRAVATO®.
Call your doctor for medical advice about side effects. You may report side effects to Johnson & Johnson at 1-800-526-7736, or to the FDA at 1-800-FDA-1088.
Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.
cp-170363v4
About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.
Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Follow us at @JNJInnovMed.
© Johnson & Johnson and its affiliates 2026. All rights reserved.
Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to product development and the potential benefits and treatment impact of CAPLYTA® (lumateperone), SPRAVATO® (esketamine) CIII nasal spray, and seltorexant. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
References:
Durgam S, Earley WR, Kozauer, SG et al. Lumateperone for the Prevention of Relapse in Patients with Schizophrenia: Results From a Double-Blind, Placebo-Controlled, Randomized Withdrawal, Phase 3 Trial. 2026 APA Annual Meeting; May 16-20, 2026. Thase ME, Krystal AD, Wajs E et al. Seltorexant, Adjunctive to Antidepressants, in Adults with Major Depressive Disorder with Insomnia Symptoms: Phase 3 Studies. 2026 ASCP Annual Meeting; May 26-29, 2026. Wegener A, Kelly R, Zhang Y et al. Impact of Seltorexant on Cognitive Performance of Adults with Major Depressive Disorder with Insomnia Symptoms. 2026 ASCP Annual Meeting; May 26-29, 2026. Poster W74. Pandina G, Mesens S, Xia L et al. Metabolic Profiles of Participants with Major Depressive Disorder with Insomnia Symptoms in a Phase 3 Trial of Seltorexant versus Quetiapine Extended Release as Adjunctive Therapy. 2026 ASCP Annual Meeting; May 26-29, 2026. Poster T30. Durgam S, Earley WR, Kozauer SG et al. Adjunctive Lumateperone 42 mg Treatment in Major Depressive Disorder: Efficacy Across Patient-Reported Depression Symptoms. 2026 ASCP Annual Meeting; May 26-29, 2026. Poster T40. Durgam S, Earley WR, Sholler D et al. Efficacy of Lumateperone 42 mg for the Treatment of Major Depressive Disorder: Analysis of Demographic and Clinical Subgroups in a Phase 3 Randomized Placebo-Controlled Trial. 2026 ASCP Annual Meeting; May 26-29, 2026. Poster W38. Earley WR, Durgam S, Kozauer SG et al. First Onset and Duration of Treatment-Emergent Adverse Events in Patients With Major Depressive Disorder Treated With Adjunctive Lumateperone 42 mg: A Pooled Analysis of 2 Randomized Placebo-Controlled Trials. 2026 ASCP Annual Meeting; May 26-29, 2026. Poster T41. Migliore R, Durgam S, Earley WR et al. Remission With Lumateperone 42 mg Adjunctive to Antidepressant Therapy in Patients With Major Depressive Disorder: Analysis of Short-Term and Long-Term Trials. 2026 ASCP Annual Meeting; May 26-29, 2026. Poster T42. Cutler AJ, Lemyre A, Zhang Q et al. Lumateperone Versus Other Adjunctive Atypical Antipsychotics for Major Depressive Disorder: A Network Meta-Analysis of Comparative Efficacy and Safety. 2026 ASCP Annual Meeting; May 26-29, 2026. Poster T36. Migliore R, Earley WR, Durgam S et al. Lumateperone 42 mg in Major Depressive Disorder: Demographic and Clinical Subgroups Efficacy Analysis in a Phase 3 Randomized Placebo-Controlled Trial. 2026 ASCP Annual Meeting; May 26-29, 2026. Poster W37. Earley WR, Durgam S, Kozauer SG et al. Metabolic Profile of Adjunctive Lumateperone 42 mg in Major Depressive Disorder: A Pooled Analysis of 2 Randomized, Placebo-Controlled Trials. 2026 ASCP Annual Meeting; May 26-29, 2026. Poster W36. Shelton R, Turkoz I, Fu DJ et al. Esketamine Nasal Spray for Relapse Prevention in Patients With Treatment-Resistant Depression: A Post Hoc Analysis of Predictors of Relapse in Placebo-Treated Patients in SUSTAIN-1. 2026 ASCP Annual Meeting; May 26-29, 2026. Poster T111. Weeks D, Cline S, Green K et al. Perspectives of Nurse Practitioners and Physician Associates on Presenting Long-Acting Injectables to Adults with Schizophrenia: A Delphi Panel Study. 2026 ASCP Annual Meeting; May 26-29, 2026. Poster T107. World Health Organization. Mental disorders. Accessed May 2026. https://www.who.int/news-room/fact-sheets/detail/mental-disorders National Alliance on Mental Health. Mental health by the numbers. Accessed May 2026. https://www.nami.org/about-mental-illness/mental-health-by-the-numbers/#:~:text=Millions%20of%20people%20are%20affected,represents%201%20in%205%20adults Key substance use and mental health indicators in the United States: results from the 2023 national survey on drug use and health. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Published July 2024. Accessed May 2026. https://www.samhsa.gov/data/report/2023-nsduh-annual-national-report Su YA and Si T. Progress and challenges in research of the mechanisms of anhedonia in major depressive disorder. Gen Psychiatr. 2022;35:e100724. doi:10.1136/gpsych-2021-10072 Pandya M, et al. Where in the Brain Is Depression? Curr Psychiatry Rep. 2012;14:634–642. doi:10.1007/s11920-012-0322-7 Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov;163(11):1905-17. doi:10.1176/ajp.2006.163. Arnaud AM, Brister TS, Duckworth K, et al. Impact of major depressive disorder on comorbidities: a systematic literature review. J Clin Psychiatry. 2022;83(6):21r14328. Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res. 2003;37(1):9-15. doi:10.1016/S0022-3956(02)00052-3 Taddei-Allen P. Economic Burden and Managed Care Considerations for the Treatment of Insomnia. AJMC. Updated April 12, 2020. Accessed May 2026. https://www.ajmc.com/view/economic-burden-and-managed-care-considerations-for-the-treatment-of-insomnia Ağargün MY, Kara H, Solmaz M. Sleep disturbances and suicidal behavior in patients with major depression. J Clin Psychiatry. 1997;58(6):249-51. National Institute of Mental Health. Major Depression. Accessed May 2026. https://www.nimh.nih.gov/health/statistics/major-depression Zhdanava M, Pilon D, Ghelerter I, et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. 2021;82(2):20m13699. doi:10.4088/JCP.20m13699 Sanacora G, Zarate C, Krystal J, et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008;7(5):426-437. doi:10.1038/nrd2462 Treatment Advocacy Center. Schizophrenia Fact Sheet. Accessed May 2026. www.tac.org/reports_publications/schizophrenia-fact-sheet/. Tandon, Rajiv et al. "The schizophrenia syndrome, circa 2024: What we know and how that informs its nature." Schizophrenia research vol. 264 (2024): 1-28. doi:10.1016/j.schres.2023.11.015 Birchwood, M. "Early intervention and sustaining the management of vulnerability." The Australian and New Zealand Journal of Psychiatry vol. 34 Suppl (2000): S181-4. doi:10.1080/000486700241 National Alliance on Mental Illness. Understanding Schizophrenia. Accessed May 2026. https://www.nami.org/types-of-conditions/schizophrenia/ Alphs L, et al. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable therapy. Int Clin Psychopharmacol. 2016;31(4)202-209. doi:10.1097/YIC.0000000000000125 Recourt K, de Boer P, Zuiker R, et al. The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder [published correction appears in Transl Psychiatry. 2019 Oct 2;9(1):240. doi:10.1038/s41398-019-0585-4 Nollet M, Leman S. Role of orexin in the pathophysiology of depression: potential for pharmacological intervention. CNS Drugs. 2013;27(6):411-422. doi:10.1007/s40263-013-0064-z Brooks S, Jacobs GE, de Boer P, et al. The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia. J Psychopharmacol. 2019;33(2):202-209. doi:10.1177/0269881118822258Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/johnson--johnson-reinforces-its-leadership-in-advancing-neuropsychiatry-with-new-portfolio-and-pipeline-data-at-apa-and-ascp-302767763.html
View Comments
- Neurovascular Devices Global Forecast Report 2025: A $7.22 Billion Opportunity by 2030, Driven by Advancement of AI- and Robot-Assisted Systems for Next-Generation Neurointerventions
May 11, 2026
Company Logo
The global neurovascular devices market is projected to grow from USD 4.64 billion in 2025 to USD 7.22 billion by 2030, at a 9.3% CAGR. This growth is fueled by increased incidence of neurovascular diseases, driven by aging populations and lifestyle factors like hypertension and smoking. Demand is also propelled by technological advancements in minimally invasive procedures. Cerebral aneurysms lead the market segment with hospitals and surgical centers being primary end-users. The Asia Pacific region is expected to experience the highest growth rate during the forecast period. Major industry players include Stryker, Medtronic, and Johnson & Johnson.
Neurovascular Devices MarketNeurovascular Devices Market·GlobeNewswire Inc.
Dublin, May 11, 2026 (GLOBE NEWSWIRE) -- The "Neurovascular Devices Market by Disease Pathology, End User - Global Forecast to 2030" has been added to ResearchAndMarkets.com's offering.
The global neurovascular devices market is poised for impressive growth, projected to climb from USD 4.64 billion in 2025 to USD 7.22 billion by 2030, at a CAGR of 9.3%.
This surge is primarily driven by the increasing prevalence of neurovascular diseases spurred by factors such as aging populations, hypertension, and sedentary lifestyles. This trend fuels the demand for advanced monitoring and treatment tools as conditions like stroke, brain aneurysms, and arteriovenous malformations become more common. An expanding elderly demographic, particularly vulnerable to these conditions, further accelerates the market demand. Continuous technological advancements enhance device efficiency and accuracy, appealing to healthcare providers and patients alike.
The report categorizes industry participants by company type, designation, and regional distribution, offering insights into the competitive landscape. Key market players include Stryker, Medtronic, Johnson & Johnson, Terumo Corporation, and Penumbra, among others, showcasing diverse innovations and strategic expansions.
Market Challenges and Opportunities
Despite promising growth prospects, the market grapples with challenges such as high treatment costs, a lack of skilled neurosurgeons, and stringent regulatory hurdles. Nonetheless, the market's potential remains strong, especially in precision-enhancing AI and robotic-assisted systems poised to revolutionize neurointerventions.
Cerebral Aneurysm Segment Dominates Disease Pathology
In the disease pathology segment, cerebral aneurysms hold the largest share of the global market. The prevalence of cerebral aneurysms is attributed to lifestyle factors, including smoking, chronic hypertension, and obesity, compounded by genetic predispositions. While middle-aged individuals and women are more susceptible, those with family histories of aneurysms face heightened risks, underscoring the segment's dominance.
Story Continues
Hospitals & Ambulatory Surgical Centers: Leading End Users
Among end users, hospitals and ambulatory surgical centers lead the market. Equipped with state-of-the-art diagnostic tools and skilled teams, these institutions manage critical conditions like strokes and aneurysms effectively. Their comprehensive care spectrum-from diagnostics to rehabilitation-ensures superior patient outcomes, explaining their market leadership.
Asia Pacific: A High-Growth Region
The Asia Pacific region is expected to exhibit the highest CAGR during the forecast period. A rapid escalation in neurovascular disease cases coupled with rising demand for advanced treatments propels this market. Major industry players are establishing a stronger APAC presence by advancing technologies and refining robotic systems to tackle complex neurovascular conditions, presenting vast opportunities for growth.
Industry Participants and Competitive Landscape
Key Insights Include:
Analysis of key drivers and restraints in the neurovascular devices market. Detailed product portfolios of major players. Comprehensive information on product enhancement and innovation. Insights into market development and diversification strategies. A thorough competitive assessment of market players.
Key Attributes:
Report Attribute Details No. of Pages 307 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $4.64 Billion Forecasted Market Value (USD) by 2030 $7.22 Billion Compound Annual Growth Rate 9.3% Regions Covered Global
Market Dynamics
Drivers
Increase in Incidence of Neurovascular Diseases Availability of Medical Reimbursements for Neurovascular Procedures Expansion of Healthcare Infrastructure Across Emerging Economies Rise in Demand for Effective Neurovascular Technologies
Challenges
Stringent Regulatory Approval Process for Medical Devices
Opportunities
Advancement of AI- and Robot-Assisted Systems for Next-Generation Neurointerventions
Company Profiles
Key Players
Stryker Medtronic Johnson & Johnson Terumo Corporation Penumbra, Inc. Microport Scientific Corporation Balt Group Kaneka Corporation Phenox GmbH (Wallaby Medical) Asahi Intecc Co. Ltd. Achieva Medical (Peijia Medical) Rapid Medical Japan Lifeline Co. Ltd. Acandis GmbH Evasc Medical System Corp
Other Key Players
Sensome Lepu Medical Technology (Beijing) Co. Ltd. Imperative Care, Inc. Medikit Co. Ltd. Zylox-Tonbridge Medical Co. Ltd.
SMEs/Startups
Neurosafe Medical Co. Ltd. Luseed Vascular Neurovasc Technologies, Inc. Oxfordendovascular Galaxy Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/h7048a
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Neurovascular Devices Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
View Comments
- Johnson & Johnson CEO: America’s innovation advantage starts with health
May 9, 2026
Over the past century, American innovation has transformed healthcare, turning once-unimaginable ideas into lifesaving realities for patients around the world.
As the United States approaches its 250th anniversary, that legacy is not slowing down.
After decades working at the intersection of science, manufacturing, and patient care, I see every day that America’s capacity for innovation is not fading. It is gaining momentum.
What sets the United States apart is not invention alone. It is our ability to translate discovery into real-world impact. Today the United States leads the world in biopharmaceutical innovation, with American companies driving 55% of global R&D and producing more new medicines than any other country. That leadership translates directly to patients, with roughly 70% of new medicines launching first in the U.S., giving Americans access to breakthrough treatments months, often years, ahead of other countries.
We are entering an era where breakthroughs move faster from lab to patient. Diseases are detected earlier. Treatments are tailored more precisely. High-quality care is reaching more people. Progress is no longer defined only by what we discover, but by how early and effectively we put those discoveries to work.
And that progress is already changing lives.
In cardiovascular care, American innovation is giving critically ill patients meaningful additional time – time to recover, to return home, to lead fuller lives. In cancer, innovation has fundamentally changed the outlook. Diseases once considered fatal are increasingly manageable, and in some cases potentially curable, as science turns the body’s own biology into a powerful tool against disease.
Artificial intelligence is accelerating this progress, and the U.S. leads here, too.
It is transforming how our scientists discover medicines, design clinical trials, and match therapies to the patients most likely to benefit. Research timelines that once spanned decades are being compressed into years, while health systems are using scarce expertise more effectively.
AI will not replace the human side of healthcare. Instead, it will amplify human judgment, automating routine tasks so clinicians can spend more time listening to patients and delivering the most informed care.
Innovation also extends into the operating room, where advanced technologies are enhancing surgeons’ skills, generating real-time insights to support better decisions and improved outcomes.
Story Continues
Yet innovation alone will not improve and extend lives.
Breakthroughs matter only if they reach the people who need care. Ensuring access and affordability is not separate from innovation, it is central to its purpose. We must meet today’s patient needs while continuing to invest in the advances that will define the next generation of care.
This balance is not easy. Many of the most transformative therapies available today were funded years before they reached a single patient. At the same time, healthcare systems face real cost pressures, and patients need solutions that are both innovative and accessible. Meeting both challenges requires partnership, scale, and a long-term view.
Here, again, America’s strength stands out.
The United States has a unique ability to bring together the institutions, manufacturing strength, and innovation ecosystems needed to deliver breakthroughs at scale, supported by policies that value innovation, investment, and patients. That foundation is why healthcare companies are deepening their commitment to the U.S.
Across the industry, hundreds of billions of dollars are being invested in American research and manufacturing. This includes Johnson & Johnson’s commitment of more than $55 billion over the next four years to expand U.S. R&D, manufacturing, and technology, building state-of-the-art facilities and ensuring that the vast majority of our most advanced medicines are made in America.
Healthcare is a uniquely powerful investment. It is both human and economic. Studies consistently show that every dollar invested can generate multiples in economic return. Health is not simply a cost to manage; it is a down payment on longer lives, stronger communities, and a more resilient economy.
Looking ahead to America 250 years from now, leadership will be judged by whether we can turn innovation into lasting value for people and for society. To me, that means investing in the one innovation that serves all of us: the health of humanity.
The opinions expressed in Fortune.com commentary pieces are solely the views of their authors and do not necessarily reflect the opinions and beliefs of Fortune.
This story was originally featured on Fortune.com
View Comments
- DARZALEX royalties drive Genmab’s Q1 revenue higher amid expansion push
May 7, 2026
Investing.com -- Genmab reported a 25% year-on-year increase in first-quarter revenue for 2026, driven by strong royalty income from blockbuster cancer drug DARZALEX and multiple sclerosis treatment Kesimpta, as the Danish biotech company continued investing heavily in its late-stage oncology pipeline.
Revenue for the three months ended March 31 rose to $896 million from $715 million a year earlier, while royalty revenue climbed 26% to $742 million. The company said growth was primarily fueled by higher sales of DARZALEX, marketed by Johnson & Johnson, and Kesimpta, marketed by Novartis.
DARZALEX global sales increased 22% to nearly $4 billion during the quarter, generating $562 million in royalties for Genmab. Kesimpta royalties rose 29% to $116 million amid growing demand and wider patient access.
Despite the strong top-line performance, net profit fell sharply to $53 million from $195 million a year earlier. The decline reflected higher research and development spending, integration costs tied to the company’s acquisition of Merus in late 2025, and increased interest expenses from the debt used to finance the $5.5 billion transaction, the company said.
Genmab maintained its full-year 2026 guidance, forecasting revenue between $4.1 billion and $4.4 billion and operating profit between $900 million and $1.4 billion. The company expects continued growth from DARZALEX royalties and expanding sales of EPKINLY and Tivdak.
The company also highlighted progress across its oncology pipeline. Rina-S, an antibody-drug conjugate targeting folate receptor alpha cancers, is advancing through three Phase 3 trials, while petosemtamab, acquired through Merus, continues development in head and neck cancers with two active Phase 3 studies underway.
Genmab ended the quarter with $1.5 billion in cash and cash equivalents and approximately $5.2 billion in borrowings related to the Merus acquisition.
Related articles
DARZALEX royalties drive Genmab’s Q1 revenue higher amid expansion push
Nvidia's new Alpamayo project: What it means for Tesla?
As Claude disrupts stock market, Anthropic researcher warns ’world is in peril’
View Comments
- Johnson And Johnson Balances Mental Health Push With Mixed Pipeline Outlook
May 7, 2026
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Johnson & Johnson (NYSE:JNJ) has launched its global "Generation Fine" campaign to address depression care and improve patient conversations. The company reported new FDA approvals and positive Phase 3 data in immunology and neuropsychiatry, alongside progress on its OTTAVA robotic surgery platform. JNJ outlined an accelerated global registration plan for JNJ-1900 in head and neck cancer. The dual target antibody JNJ-4804 for inflammatory bowel disease did not meet its main Phase 2b endpoint, but the company plans late stage trials in a specific high need subgroup.
Johnson & Johnson shares recently traded at $224.62, with the stock up 8.3% year to date and 46.8% over the past year. Over 3 and 5 years, returns of 51.9% and 53.8% respectively suggest the company has been a steady large cap healthcare holding for many investors. The current value score of 3 indicates the stock may not screen as especially cheap or expensive on the framework used here.
For investors watching NYSE:JNJ, this mix of patient focused initiatives, regulatory milestones, and mixed trial outcomes adds fresh detail to the current investment story. The key question is how much weight to give the expanding late stage pipeline and medical technology efforts, such as OTTAVA, relative to the risks that come with complex immunology and neuropsychiatry development.
Stay updated on the most important news stories for Johnson & Johnson by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Johnson & Johnson.NYSE:JNJ Earnings & Revenue Growth as at May 2026
Is Johnson & Johnson's dividend sustainable? Check out what every dividend investor needs to know in our dividend analysis.
Quick Assessment
✅ Price vs Analyst Target: At US$224.62 versus an average analyst target of about US$252.42, the stock trades roughly 11% below consensus. ✅ Simply Wall St Valuation: The shares are flagged as trading about 40% below an estimated fair value. ❌ Recent Momentum: The 30 day return of about 6.8% decline shows short term weakness despite the positive newsflow.
The timing of any decision to buy, sell or hold Johnson & Johnson depends on each investor's own judgment. For more detail, visit Simply Wall St's company report for the latest analysis of Johnson & Johnson's Fair Value.
Key Considerations
📊 The Generation Fine campaign and recent approvals support the mental health and immunology story, while the trial setback shows pipeline risk is still present. 📊 Monitor how JNJ-1900 progresses through global registrations, the uptake of new FDA approved products, and any updates on the OTTAVA robotic surgery platform. ⚠️ The high level of debt and recent insider selling sit alongside the mixed trial result as key risk points to watch.
Story Continues
Dig Deeper
For a fuller picture, including more risks and potential rewards, explore the complete Johnson & Johnson analysis. You can also visit the community page for Johnson & Johnson to see how other investors believe this latest news may influence the company's narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include JNJ.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- Darzalex, Erleada & New Drugs Keep J&J's Oncology Engine Charged in Q1
May 7, 2026
Johnson & Johnson JNJ is one of the key pharmaceutical players in the oncology segment with significant expertise in blood cancers and solid tumors. It is the #1 company in multiple myeloma, with key drug Darzalex being considered the gold standard in multiple myeloma and J&J’s #1 product.
Its Oncology segment comprises around 29% of total revenues and 45% of its Innovative Medicine segment sales. Its oncology sales rose 17.8% on an operational basis in the first quarter of 2026, driven by strong market growth and share gains of key products such as Darzalex and prostate cancer drug, Erleada. The sales growth was partially dampened by lower sales of Imbruvica.
In the first quarter, Darzalex rose 22.5% year over year to $3.96 billion, while Erleada generated sales of $949.0 million, up 23.1%. Imbruvica sales declined 6.9% to $660.0 million due to continued rising competitive pressure in the United States.
J&J’s new cancer drugs, Carvykti, Tecvayli, Talvey and Rybrevant/Lazcluze are contributing significantly to top-line growth driven by market share gains. Combined, they generated $1.2 billion in sales in the first quarter of 2026.
J&J expects the momentum to continue and targets its oncology sales to reach $50 billion by 2030. Though quite bullish, J&J seems quite confident that it can meet the target, citing strong growth in its marketed cancer drugs and new launches like Rybrevant and Inlexzo.
J&J’s newly launched therapy, Inlexzo, the first-of-its-kind drug-releasing system for treating certain types of bladder cancer, generated sales of slightly above $30 million in the quarter. On the call, the company said that it received a permanent J-code for Inlexzo reimbursement in April that should boost patient access and sales for the therapy.
J&J believes its new cancer drugs, Talvey, Tecvayli, Inlexzo and Rybrevant plus Lazcluze, have the potential to deliver peak sales of $5 billion.
Meanwhile, J&J’s oncology pipeline has gained strong momentum in the last couple of years with promising developments in colorectal and head and neck cancers. In the first quarter, J&J gained FDA approval of Tecvayli plus Darzalex Faspro for relapsed/refractory multiple myeloma. This combination regimen has the potential to become a new standard of care in earlier lines of myeloma treatment.
J&J is also building its oncology pipeline through M&A deals. Last year, it acquired Halda Therapeutics, which added a promising clinical-stage treatment for prostate cancer with potential across multiple tumor types.
Story Continues
Competition in the Oncology Space
Other large players in the oncology space are Pfizer PFE, AstraZeneca AZN, Merck MRK, among others.
Oncology sales comprise around 26% of Pfizer’s total revenues. Its oncology revenues grew 7% in the first quarter of 2026, driven by higher sales of drugs like Lorbrena, the Braftovi-Mektovi combination and Padcev, which made up for declining sales of Ibrance, Xtandi and others. Pfizer also has a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, ADCs and immuno-oncology biologics.
For AstraZeneca, oncology sales now comprise around 45% of total revenues. Sales in its oncology segment rose 16% at constant exchange rate (CER) in the first quarter of 2026. AstraZeneca’s strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck’s pharmaceutical sales. Keytruda recorded sales of $8 billion in the first quarter of 2026, up 8% year over year.
JNJ’s Price Performance, Valuation and Estimates
J&J’s shares have outperformed the industry over the past year. The stock has risen 44.3% in the past year compared with 20.9% appreciation of the industry.Zacks Investment Research
Image Source: Zacks Investment Research
From a valuation standpoint, J&J is slightly expensive. Going by the price/earnings ratio, the company’s shares currently trade at 18.84 forward earnings, higher than 16.84 for the industry. The stock is also trading above its five-year mean of 15.65.Zacks Investment Research
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings has risen from $11.54 to $11.57 over the past 30 days, while that for 2027 earnings has gone up from $12.45 per share to $12.58 over the same time frame.Zacks Investment Research
Image Source: Zacks Investment Research
J&J has a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN) : Free Stock Analysis Report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
Pfizer Inc. (PFE) : Free Stock Analysis Report
Merck & Co., Inc. (MRK) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Why This Income Pro Likes Banks, Chip-Equipment Companies, and More
May 7, 2026
Michael Barclay, lead manager of the Columbia Dividend Income fund, favors dividend growers over high yields.
Continue Reading
